UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors

The American journal of surgical pathology, 2017-03, Vol.41 (3), p.326-333

2017

Volltextzugriff (PDF)

Updates in gynecologic care for individuals with lynch syndrome

Frontiers in oncology, 2023-03, Vol.13, p.1127683

2023

Volltextzugriff (PDF)

Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors

Gynecologic oncology, 2017-03, Vol.144 (3), p.607-612

2017

Volltextzugriff (PDF)

Role of Minimally Invasive Surgery in Gynecologic Oncology: An Updated Survey of Members of the Society of Gynecologic Oncology

International journal of gynecological cancer, 2015-07, Vol.25 (6), p.1121-1127

2015

Volltextzugriff (PDF)

Two birds, one stone? The risks and benefits of combined prenatal carrier screening and hereditary cancer screening

Cancer, 2024-09

Ring, Kari L

2024

Volltextzugriff (PDF)

Current and future role of genetic screening in gynecologic malignancies

American journal of obstetrics and gynecology, 2017-11, Vol.217 (5), p.512-521

2017

Volltextzugriff (PDF)

Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy

Frontiers in immunology, 2018-09, Vol.9, p.2102-2102

2018

Volltextzugriff (PDF)

One size may not fit all: The debate of universal tumor testing for Lynch syndrome

Gynecologic oncology, 2015-04, Vol.137 (1), p.2-3

2015

Volltextzugriff (PDF)

Factors affecting adherence to a high-risk surveillance protocol among patients with Li-Fraumeni syndrome

Hereditary cancer in clinical practice, 2023-08, Vol.21 (1), p.15-15, Article 15

2023

Volltextzugriff (PDF)

Endometrial Hyperplasia

Obstetrics and gynecology (New York. 1953), 2022-12, Vol.140 (6), p.1061

2022

Volltextzugriff (PDF)

Para-Aortic Nodal Radiation in the Definitive Management of Node-Positive Cervical Cancer

Frontiers in oncology, 2021-04, Vol.11, p.664714-664714

2021

Volltextzugriff (PDF)

How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations

Gynecologic oncology, 2024-05, Vol.184, p.8-15

2024

Volltextzugriff (PDF)

TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers

Modern pathology, 2019-08, Vol.32 (8), p.1168-1179

2019

Volltextzugriff (PDF)

Mesonephric-like Endometrial Carcinoma: Results From Immunohistochemical Screening of 300 Endometrial Carcinomas and Carcinosarcomas for This Often Overlooked and Potentially Aggressive Entity

The American journal of surgical pathology, 2022-07, Vol.46 (7), p.921-932

2022

Volltextzugriff (PDF)

Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas

Modern pathology, 2018-08, Vol.31 (8), p.1282-1290

2018

Volltextzugriff (PDF)

Somatic Sequencing and Microsatellite Instability Results From Mismatch Repair-deficient Endometrial Carcinoma Patients Without Lynch Syndrome ("Lynch-like" tumors): Implications for Heritable Cancer Screening, Molecular Prognostication, and Immunotherapeutic Vulnerability

The American journal of surgical pathology, 2023-08, Vol.47 (8), p.878-888

2023

Volltextzugriff (PDF)

LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy

International journal of gynecological pathology, 2020-05, Vol.39 (3), p.203-212

2020

Volltextzugriff (PDF)

What About the Others? Clinical Management of Gynecologic Cancer Risk in Patients With Moderate-Risk Hereditary Cancer Genes (ATM, BRIP1, RAD51C, RAD51D, and PALB2)

Clinical obstetrics and gynecology, 2024-09

2024

Volltextzugriff (PDF)

Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers

Gynecologic oncology reports, 2019-05, Vol.28, p.18-22

2019

Volltextzugriff (PDF)

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

Current treatment options in oncology, 2018-12, Vol.19 (12), p.70, Article 70

2018

Volltextzugriff (PDF)

Yolk Sac Differentiation in Endometrial Carcinoma: Incidence and Clinicopathologic Features of Somatically Derived Yolk Sac Tumors Versus Carcinomas With Nonspecific Immunoexpression of Yolk Sac Markers

The American journal of surgical pathology, 2024-07, Vol.48 (7), p.790-802

2024

Volltextzugriff (PDF)

MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition

Modern pathology, 2021-03, Vol.34 (3), p.627-636

2021

Volltextzugriff (PDF)

Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort

Modern pathology, 2016-11, Vol.29 (11), p.1381-1389

2016

Volltextzugriff (PDF)

PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions

Gynecologic oncology reports, 2017-05, Vol.20 (C), p.135-136

2017

Volltextzugriff (PDF)

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Clinical cancer research, 2021-05, Vol.27 (10), p.2734-2741

2021

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(54)
Mit Volltextzugriff
(38)

Publikationsform

Sprache

Englisch
(60)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors

Updates in gynecologic care for individuals with lynch syndrome

Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: A comparison of matched primary and metastatic tumors

Role of Minimally Invasive Surgery in Gynecologic Oncology: An Updated Survey of Members of the Society of Gynecologic Oncology

Two birds, one stone? The risks and benefits of combined prenatal carrier screening and hereditary cancer screening

Current and future role of genetic screening in gynecologic malignancies

Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy

One size may not fit all: The debate of universal tumor testing for Lynch syndrome

Factors affecting adherence to a high-risk surveillance protocol among patients with Li-Fraumeni syndrome

Endometrial Hyperplasia

Para-Aortic Nodal Radiation in the Definitive Management of Node-Positive Cervical Cancer

How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations

TIM-3 in endometrial carcinomas: an immunotherapeutic target expressed by mismatch repair-deficient and intact cancers

Mesonephric-like Endometrial Carcinoma: Results From Immunohistochemical Screening of 300 Endometrial Carcinomas and Carcinosarcomas for This Often Overlooked and Potentially Aggressive Entity

Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas

Somatic Sequencing and Microsatellite Instability Results From Mismatch Repair-deficient Endometrial Carcinoma Patients Without Lynch Syndrome ("Lynch-like" tumors): Implications for Heritable Cancer Screening, Molecular Prognostication, and Immunotherapeutic Vulnerability

LAG-3 and GAL-3 in Endometrial Carcinoma: Emerging Candidates for Immunotherapy

What About the Others? Clinical Management of Gynecologic Cancer Risk in Patients With Moderate-Risk Hereditary Cancer Genes (ATM, BRIP1, RAD51C, RAD51D, and PALB2)

Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers

The Role of PD-1 Checkpoint Inhibition in Gynecologic Malignancies

Yolk Sac Differentiation in Endometrial Carcinoma: Incidence and Clinicopathologic Features of Somatically Derived Yolk Sac Tumors Versus Carcinomas With Nonspecific Immunoexpression of Yolk Sac Markers

MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition

Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort

PD-L1 pitfalls: Emphasizing the importance of membranous localization and correlation with tumor cell and macrophage distributions

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Suchergebnisse filtern